Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Free Cash Flow (2021 - 2026)

HeartSciences (HSCS) has disclosed Free Cash Flow for 5 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 6.9% year-over-year to -$2.3 million, compared with a TTM value of -$7.5 million through Oct 2025, up 5.53%, and an annual FY2025 reading of -$7.4 million, down 20.89% over the prior year.
  • Free Cash Flow was -$2.3 million for Q4 2025 at HeartSciences, down from -$2.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$717491.0 in Q3 2021 and bottomed at -$2.3 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$1.5 million, with a median of -$1.6 million recorded in 2025.
  • The sharpest move saw Free Cash Flow crashed 153.52% in 2022, then grew 23.21% in 2025.
  • Year by year, Free Cash Flow stood at -$768053.0 in 2021, then crashed by 40.63% to -$1.1 million in 2022, then increased by 8.33% to -$990139.0 in 2023, then tumbled by 120.53% to -$2.2 million in 2024, then fell by 6.9% to -$2.3 million in 2025.
  • Business Quant data shows Free Cash Flow for HSCS at -$2.3 million in Q4 2025, -$2.0 million in Q3 2025, and -$1.6 million in Q2 2025.